GlassScriptPhysician profile
Rachel Pierce
NPI 1609412634
$5,256.07
in general payments reported to CMS, 2019-2025
21 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,584 · 2023: $1,350 · 2024: $1,186 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604 · Education: $68.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,604.20 |
| Education | $68.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.60 | 2022-2025 | |
| Gilead Sciences, INC. | $472.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $402.99 | 2022-2025 | Entyvio |
| Celgene Corporation | $341.79 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $324.21 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $287.73 | 2023-2025 | Dupixent |
| Pfizer INC. | $257.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $237.62 | 2022-2023 | |
| Janssen Biotech, INC. | $197.98 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.71 | 2022-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $122.92 | 2022-2025 | Ocaliva |
| Genzyme Corporation | $107.00 | 2023-2025 | |
| Celltrion USA INC. | $94.30 | 2023-2024 | Zymfentra, Yuflyma, Vegzelma |
| Nestle Healthcare Nutrition INC. | $75.13 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.74 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $46.27 | 2024 | Ibsrela |
| Qol Medical, LLC | $41.24 | 2022-2024 | Sucraid |
| Madrigal Pharmaceuticals | $36.58 | 2024 | Resmetirom |
| Merck Sharp & Dohme LLC | $32.91 | 2023-2024 | Dificid |
| Mirum Pharmaceuticals, INC. | $27.04 | 2025 | Livmarli |
| Sandoz INC. | $24.87 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.